Cancer immunology, immunotherapy : CIIHumansMaleFemaleCarcinomaNon-Small-Cell Lung
Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.
Qianyi Wang, Anwen Xiong, Chenyu Mao, Wenxiang Wang, Jiuwei Cui, Jian Fang, Wu Zhuang, Kunyu Yang, Wei Zuo, Jun Yang, Lika Ye, Zhiye Zhang, Zengmei Sheng, Zhe Liu, Donglin Wang
Published: 202610.1007/s00262-026-04299-x
Abstract
OBJECTIVE: To evaluate the efficacy and safety of the anti-lymphocyte activation gene-3 (LAG-3) antibody IBI110 in combination with sintilimab and chemotherapy in patients with advanced squamous non-small cell lung cancer (sqNSCLC). METHODS: In this…
Preview only. Read the full abstract at the source